-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TFRSuPNjL+nsmPgJJnLIPWKup5toK+i6M1nDI2XFtm6jh9XWeO3+PDzyWzs9l2wX
 cRFtmN9LUkSf4A9UiEyI4w==

<SEC-DOCUMENT>0001193125-10-247409.txt : 20101104
<SEC-HEADER>0001193125-10-247409.hdr.sgml : 20101104
<ACCEPTANCE-DATETIME>20101104104333
ACCESSION NUMBER:		0001193125-10-247409
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101104
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101104
DATE AS OF CHANGE:		20101104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		101163596

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): November&nbsp;4, 2010 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not
Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:18px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
November&nbsp;4, 2010, ARCA biopharma, Inc. issued a press release announcing that it has received notification of a grant of $489,000 under the Qualifying Therapeutic Discovery Project. The press release is attached as Exhibit&nbsp;99.1 hereto, the
contents of which are incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma awarded $489,000 grant under Qualifying Therapeutic Discovery Project&#148;, dated November&nbsp;4, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:12px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;4, 2010 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>ATRICK</SMALL> M.
W<SMALL>HEELER</SMALL> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patrick M. Wheeler</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Chief Financial Officer</B></FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:12px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma awarded $489,000 grant under Qualifying Therapeutic Discovery Project&#148;, dated November&nbsp;4, 2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="font-size:1px;margin-top:12px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1
</B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g116154g05y32.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA AWARDED $489,000 GRANT
UNDER QUALIFYING </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THERAPEUTIC DISCOVERY PROJECT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;&#150;
 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA is developing the first potential genetically-targeted therapy for heart failure </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, November&nbsp;4, 2010</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has received notification of a grant of
$489,000 under the Qualifying Therapeutic Discovery Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Qualifying Therapeutic Discovery Project Credit is provided under section
48D of the Internal Revenue Code (IRC), as added to the IRC by the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased to receive grants under this program to support our further development of new cardiovascular therapeutics,&#148; said Michael
R. Bristow, President and Chief Executive Officer of ARCA. &#147;Our current lead development program plan includes the first full-sized cardiovascular trial performed in a genetically defined population designed to increase the efficacy of the drug
according to a patient&#146;s genetic make up. We believe this personalized medicine approach to drug candidate development offers the possibility of improved health outcomes for patients and more cost-effective healthcare.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About
Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM
</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is an oral tablet
formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would
otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro is well-tolerated in patients with advanced HF. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;17, 2010, ARCA announced that it reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess
the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. An SPA is an agreement with the FDA that the proposed trial protocol design,
clinical endpoints and statistical analyses are acceptable to support regulatory approval. The FDA has previously </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:12px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">designated as a Fast Track development
program the investigation of Gencaro for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. ARCA has been awarded a patent from the U.S. Patent and Trademark Office (March
2010) and a patent from the European Patent Office (October 2010) on methods of treating heart failure patients with bucindolol based on genetic testing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Heart Failure </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heart failure, or HF, is a chronic, progressive condition in which a
problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body&#146;s needs for blood and oxygen. Common causes of heart failure include myocardial infarction and other forms of ischemic
heart disease, hypertension, valvular heart disease and cardiomyopathy. Heart failure is one of the largest health care problems in the United States and the rest of the world. Industry sources estimate that about 5.7&nbsp;million Americans have HF
and nearly 670,000 new patients are diagnosed annually. In addition, HF is the underlying reason for approximately 12 to 15&nbsp;million annual visits to physicians, 6.5&nbsp;million annual hospital days and over $37 billion in direct and indirect
annual healthcare costs in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beta-blockers are part of the current standard of care for HF, and are considered to be among
the most effective drug classes for the disease. However, a significant percentage of eligible patients in the United States is not being treated with, or does not tolerate or respond well to, the beta-blockers currently approved for the treatment
of HF. ARCA believes that new therapies for which patient response can be predicted before a drug is prescribed can help improve the current standard of practice in the treatment of HF. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing
genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being
developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating
with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please <U>visit www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148;
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ARCA&#146;s development program potential to be the first
genetically-targeted therapy for heart failure. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business
objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and
technological changes. These and other </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2009 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g116154g05y32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g116154g05y32.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`30#<`P$1``(1`0,1`?_$`,````$$`P$!`0``````
M``````@`!PD*`0,&`@4$`0$``00#`0$`````````````"`4&!PD!`P0""A``
M``4#`P(#!`0,!`4%`0```0(#!`41!@<`$@@A$S%!"2(R(Q1188$5\'&AT4)2
M@J)#8Q8*D;%B%[(S)"48P9+B1%0F$0`!`P($!`0!!@H)!0```````0(#$00A
M$@4&,4$'"%%A(A-Q@9&AL3(4P='A0G*2(S-C)/#Q4F*S%74V.$/3--0G_]H`
M#`,!``(1`Q$`/P"[AR!Y!0&"()!Z]1-,W#+"=.W[;;JIIJNSD+\9Z^6,`F91
M+3H*BE#&,8=I0$=1Z[@NX?;/03;B:GJS'7&K3)2"!*_M'<N&-./-"[-I;/OM
MW:@EM;O]J!F+G+2B^6/,B_F>:/(BXWRBL=<;"U4!,=1&/AH.*7102,("1)1S
M,,I%=T(%\#"*8_Z=:D]U]]_<)KNIK=:%>_Y/82O_`&<,<%K(K47@BK-%*[AQ
MJIGRVZ7[6TZ'^>@;.J)17+(],?'TN:G)>1^Y'D9R>,"2A\E.Q3<)E72__GK4
M`HD/40*4P0(;MNT?IU]Q]T/=A<VR+#N6Y1Z_G?<]/_\`4H==OL_8'N*V:Q8J
M)_$F_P"X?0>Y]Y0M`1*;(\@4RT<T>`92W[2$*.$]P"`!;_Z0=0U5=9[CN[2P
M@AN4W+<HRXM&/:GW/3_M*F*_^)\/+R.N#:6P'+.CK)BY.'[2;#C_`!#G)#E%
MR:B54Q7R*Y.*92'.FK`VH4A]]1*14"P)54ZEH(#TJ`ZH%]W;=T.C7/M76Y9Y
M)FM1RL6SL$K\UJB_25"WV!L:\D8D5DQK%8F/N2\<<?W@1.$.=<I(S#&V<P),
MFR,@NDT:7C&M08H-G"]2$+-L=RS8K45*!\PB8`+6IB`%:2J[?^_N[U[5;/:G
M4RV1)IY4C6\5J1T<M$;F1F5GJ7P:61O+I+%IUM)J.BOK&S'VZJJT\E7'#SK^
M$DQ1=&4(!M]:AN`2[3$,4Q0,0Q#``@<AB&`0-^EK:4QS7P_>;=R2P2(CF*G#
M*J)PI\_/B8%5KV(Y[ZHC%6J?`W]U3];\A?S:[`BU2OB+NJ?K?D+^;0Y&*Y(<
MD<8\4L171FW,<TZAK%M(\8G(N&,>,I)NG4Q((1K"/B(Q!5->1>+KN*@F`@)4
MTSG&H%T`[5MW''W3`0MSP;].2@[CB(N>A9%$"BWD(F78H2,>^0&E.VZ:N2G`
M*C0!#KH#[?=4_6_(7\V@&PS#FG'N!+"E<FY6N!6V;(A5F+>4FD8.<N`[161=
M)LV8FC;<C964,B9PJ&\Y4#$(7J82AUT`%C'U??3?D!5*GRVQZV.F84U$I*.N
MR+725*`[TU4G]N(*)+$\1(8`,'F&@/SK^L/Z<2#@[5#E':\RY2_YB-OVM?TZ
M<O2HF.6)M1T)24&M1H%-`.1BKU+>"^:YQ"V<=<H<725R.U@;M;>FY1>S9IPY
M$U"MVS"\6<&NZ76'H1,E3F-T`!$::`.+NG_6`?/H!1`0'P$!`*"`Z`7=4_6_
M('YM`<]=5X6W9%OR=U7E<L':=M0J(N9:?N.5CH.&CD"@`BJ^DY-9LS:I@`@/
MM'`1J`!41IH"."7]8?A'_4CBT,<7CD+/]SM%10=1''K$-_96%`Y0'<H,I"PI
M(91`!`0`Y7`E&GCH#G;F]9GBOC\$E\KV+RNPY&KG`B4UD[C1?]MPQA$P$"LB
M+9VB`B8?.G7RT`1''?U&.'G*N[_Z!P3FZ*O6]BP;RY%+6/;]S04L6%C5&R4B
M^!*=A8M)0C,[U,IP*H(ANJ%0`=`&UW3^1ZAY#0HU#R&M.M=`+NJ?K?D+^;0`
M[<F.4^).(V.FN4LVW"Y@K2?WA:]D,UH^--)OW$Y=;]-BP208)JD.JU9D!5T\
M6`VUNS144'W::`(-N[!PDFX0<)N&ZZ**[==$2J(K(+)@HDLDJ6I%4U2#N`Q>
M@@(:`W=U3];\A?S:`V[S=K=7KNI6@?FIH"$OFS(2$KR*G6"ZRIFT'!VQ'QZ0
ME,=!%LZB4I1X)0Z@0Z[E^(F&E/8#6B/OTUK5[ON"O=,O)))-)L(;/V(\',8L
MEI$YZY4J[%[G+PXJ2=Z86=G;;6@U%V$DCI<RIQ6DCD3Z$0YG&N/6MP&19**I
MLY%6GR+I82@S=J*T$C-RX.&U'O#[)#C0H#0*]=8[Z2],(MS1/DO$9]^F7.R2
M15:VM<&(BT6JUJF%,#W:_K2VDRR19G62X94Q<CN.9>65$14XUJJ8!76[B51]
M;\K&K1:B$_:JH2";!5`/F58AW\%^PV`4PJ'1=D!9,2^\!A`!H(:G'MOHVMSM
M>YTUMFK-Q6B-5&.2GO-K2L;_`+/GZG)@8UOMPI!,V1'UC?7@O!>/]/,<67PR
MBM*PSAZU.C#1=GPTC+K"B!$A&,:JBJP%0Q`("[M0@)B6M2E,(^6LG;DZ)0W-
M]IDCK>-ND6.EM=<.P=[:M1*M5&*Y5<N-*(O`IEKN63-*Q<V>5]&XIX\_@G-/
M`&:\\9&=-'-R2Y09-7KAZ=D4J1._+.E%5%3,XI`P%.#-!+JHN`;2%`"EJ--1
M,WYT@CNF7.\9($M].N'.]C.J->L:<%R5KS7D9`TK6O;1EM[E9$1*JB@:75!J
ML5UE"E%(#D$033\"%Z%H!3[5"U`?$0KJ!^Y]-GTJ_?%'[D<S'^[&[@F:-<S5
MKQXH9.L)K62%7SJZ3,Q6TKXI2OR$[?'J:?7#A/&4O)*F</G-J1R;E=41,JL9
MF4S(%3F'J910C<!$1\QU^B;MUU[4=Q]#]MZY=.S7,]C5V;%5R/D9BJ?H?,1`
MWA`VWW%<Z?!Z8<ZK\BI4>?6:T6J57B4)$HE/`6N057?7\R9?F8)!UQWQ@T6E
M;'XOV="\B>2;MFL8K6(>7K+HV/CEB^2`QD5U(EG)+2)D1&I2N>\(43J`!_\`
MH4\F1SKPHB+`G)'YV]N.<RIC*5!151=XO::K;[XL*0<'4,*AZPZQV(#T`!8T
MT!-'UZ5"@T"H#Y5"M.G30'DQ1,`A7V1(8HA0!`1&E-P&`0,3Z0\]`5"/[D'&
MEB6GDCC;>UMVK!P-SWQ;F16%VRL+&LHE>XTX"0MEU$K3(LFZ0OW;'[P4*FLH
M)E`(82"82TH!-;Z.F-[#MKT]>-\U$6C;S29O&SWUS73-)1##[WN&=?7+/(N)
M"6?G04=.E?EVR9"[CFVD+0.F@!/]>+AKB&\^*%U<E(JS;>MW+.&Y&VY,UT0L
M4QC)&Y+2EIME`2UOW`LQ;H#*(M322+MH=;<JW5;T*?:<0T!R']OERWR)F/&6
M5<`9-G96ZG6#PM25L"?FUU7LJC8USA(,SVN\DEQ,O(-K>EHP19G5,91-NY[5
M1*F70$W/)#D'CWBWAB_,XY/?F9VG8D2+Q5!`2C(SDNZ,1M!VU"HFZN9F=DED
MVZ!``:&/N-[)3"`%3?!,-R+]>'E-.3F<KIG++XH8F>MIB:L&U7:[6UX-J_4K
M;^/H,Y3E1D[YN%FB9:0FG!%ED6Q#BB5*J(:`MRX=PCBS`%E1>/</6#;&.;2B
M6Z3=K$6S&),@6(F4`[\F[V_/RTBJ:HJN7*JRYSB)A/UH`'=W!;\)=<5(6_<\
M/%7#;\JW5:2<)/,&DU%2354G;5;OHZ20<-%T5B&$#%$M*#H"`=IP(M_@YZJW
M&_-F!("68X(Y$M\J8UO&THYE(2L7B^]9"SI&=:@W700=#%61<8Q:8M2.C`BQ
M=MS)$.":B9"@6$OP_#PT`O:_1+N^H!#=_P"WQ_\`30%0+U],FWWGR_;BL.P6
M3B4PCPH3LLF99AHN)6+7,>=.ZV@&2Y"5*_/;]N,2-Q__`"+/E2C0U*@3:>CQ
MR94Y+<&L8OYM^H^OW%95\/7UWC]QZH_LMLU1MV3=;A%4ZDW9J[!<3C[ZH*>9
M3:`E(*-0`:4J`"(5`:#YA4!$!I]6@-_\']K0$,O*%LY/RCO0[8J@G.QM`*I$
M,81I;$4&TVTIPI3Z0I36B#N[MDF[M]<]3V_L=-XM5[5_D+?@VCOEPXDG=BP_
M_/[67,B>J;FB?]5X]6,8)C(D:(35H31P.!"C*P#1RV=>\4H'>18HJ1+PA3>Z
M<O;.)>M-25Z4:+I.K6=KI>J:7<O@<K5^\1,>Q8U3'/1,JJG%.',LC7+BX196
MQ2,1U%XN3Z,?QCAW5D>2_K)3'L))N$&EIM6L9+SIBD:S<L\<H)+E9*N40%=%
M@R(J5,0`^\ZGC763]W=57W>\9=@[0NZ:;ID*,EG5BMGJE&Y:JU'NX+YE&T_0
M6-TEVIWU7*]:HG'YD\^.`]<'&G;PBCX)17>"?Q&CQ95RU=@`=2.4ESJ$4*>G
M6H5_PUG#;D#M'VVW4W72RWJMS212/SME92JHZJJE/C3B4#4IFOGK$E,>2'$Y
M"C8:;;(7,[C+CN%1VR`K2+8HG0AHPK<12,V%VR05<BCWTS&$J8`8:]1U9?4W
M2-N:UIC-PW-M<7N:)$CCA1WLQHE:1HUJHWTUJJHG/BIZ-*DECF1BO:U$\5Q6
MO-<4^DCJRZQ>F^9-]U!%(E$0(R08+H)@3H(&$[E(73@0\S',-/'6JGKK:M;[
MTLEFZU>U%1B9%3!>-5IX>*F=-N2J]S&YT7!<*HO(E,XP%,7`6+RF]X+;+Y4_
M^Z[H%.E-;D.U+_CGM7_3I/\`'G(\;U_WE=?%/J'[U(1OV4^!;J\3@,JY)MG#
MN-;[RK>3PC"U<>6I-WA/.CF*7;'03%5^JB3=[SAX*((I%"HF44``"M-<G!$7
MZ;&`EN0'$_D7G+/,7W+O]22=O>\+H;OT2JNH/%\DWE+4QA"-R*>V5O#0QQ=-
M2AL*4#)F#P#0$'/H]Y-G^%'J175QIR0X5C660IFYL`W4BY4.1LE?UKS3QY8,
MPH`F!--65=-S-B'`*"C)EJ(@`:`N]"%.E*4\0J!A`?,!$.@B`Z`QH"J#_<Q=
M9[B"%0#_`+7E[J/@'Q;+ZC3K30$O?I09!L&/].KBJS?7Q9K!['8V42?LGMS0
MS1VQ.6Y;B4,1ZU<R"*[4P)FW"!P*8`ZTIH`)_60YB65ES#3CA!Q>>AR'SGF.
MX[<93MMX@(-_%M:UH24;W`Z^]9"WC.XYI*2;UDW130,J)D41.JL!"4-H`D/1
MV].ZX>#.(KJN#*AV1LX9F7AY"[8F.<$?,;&MZ%([&!LTDFA5K)RJ*S]9>062
M$417.5-,QRI@<P$<_P#<I9CEVB?&K`3%XJVA9<MW97N5NFL8I))S%':VS:H.
M$`#8H$8LZ>K)U&A5#;O$"B`$E7H;XEB\8^G?B:<:LTDY?+LE<^4)YZ*9`<.5
M9*;=P\,FJH`;C),H2%0(D4?<*/0`J.@)>```"@?6/^(B(_XB.@,Z`P(5`P=0
MWDV&H(A4O7H-/HJ/U]=`9T`QW)7.=L<:,#Y5SO=RR2<-C*S)BY!0.;8I)R2#
M<R4'"HF]X[B;FE4&J9"]1,KYZ`BVX9\+Y'*'IIY:@\UI$5S'S_9W_G3)TG(H
M@=Y&W5DL#RV-$Q!6IR)VDV0CG*):%*BH)P*`5T!#GZ!N=IG`W,3(G%>_%3PZ
M.7F,M;HQ:ZXD3C,Q8E<3`_+D(8!*#J3B$9)J--ICG23"H^SH"Z*%*%H%`$H#
M0`VAU`!Z%\@T!O\`X/[6@(:N3KQPARBO0B"C@IBM+1.`-U12-UM6*`/:`Q>M
M?I$/QZT9=U^H7-AW;:V^W>J.]G3L%P1/Y"W))[(;;2;$MF2,J_--R_BO'TQ=
M<*C!NT4F[]EF)``BH1</(O961,1$.I%S`JM&QY!#J8#',/2E!U)[I3N:2QM8
M=0UC7[R.T5C6K;V[WYWU5%RI1S<,/$LG7=(AE<K(H$>][J56E&\Z^/(^%F:T
M;LMR]E\KVU"S4K:MXM6\C+MVB`O9Z!?(HI(J.W\>T(HL:.D4&R:I'!2&[:@B
M!J!0=6AUWV+NW9&]G]5-K6=YJ&T-5C;.]D3JWC.=7>I%1/6OYY4=O7UC/I4F
M@ZI-[6HPK2)R?9YI1%\L*IR/HVED.YKO[,+;<5+/'1P$BH+MW#1JTHF)E#R#
MQV5)LR22*%3&.8*^`5$::J6Q^H&M[X:FW-NV5^EVYN25[H51/;X+59,J'FUO
M2-*TUF=DC7_#\`^MU/V]J0S.U'5UW!;LM'QP*G>(IN3V_+K._BKN3?=IQ=I-
MOFUC$`X%Z%*`B&I$;LOK';.DVVV%U+4--UR*T9E1%RVSF+F1KU2*169E5'(J
MY<RHB5Y%HZ<UMS<>\ELV5F:B8)5*<L>/CRH1W9?E98PN"N9@\FB<#$*\:2:S
MUH82CNZN`6,=*OD4Y2B/AK6!U\U36IKZ2TU"]6]A5JKF1RJW"M*UY_(9QVW!
M'&YCVVR1+1?4B)X<"4GC"83X#Q@8?$;<+4:UK_UCOK7SKK<%VK?\=MK?Z=)_
MCS$>MZ?[RN?D^H?K\0"/XOP\M2`;]E/@6ZO$@U]9"]+AR\ZXX>F_C&7487WR
MYR"P<7X]:E.N>VL-VF]*[EY20;HJ)*+1[R1;"L8F\I5$8Y0IJE,.N3@(&VN%
M?-VSK<@+1MCU,)^&MRV8:,MZ#B&/%?#0-XV'AFB$=%L68?,&$J;1BW*2IMXF
MIN,(CUT!6>]7[BSFOB/R0QUGFYLQ/LO77ED$;K0RL2PH3';E#)F-W46DBQ5@
M[45/$I.V\:DQ>%7*)3K"57<4:5T!<DXH9[A.3O'+#N=(55+MY&LB*EY)J00K
M'7*V2%A=40H!:@FM%3[-RB)1H-"`-.H:`(;0%4#^YB$0G>((E]X(K+PEZ[>H
M*66(>U0U.OG0=`$=Q!]+/ASRO]-#!LE=N*+>MO+.0,7R#T^:;8:JQM\L;G&;
MGFT;./WC5=)I-I(_+)%7:ND3H.$2B40*-#`!#=PFSYDGT@N=-X8JS1$BSL5S
M.H8]S<Q91X"D-NJ.SN;1R[:8F)\PLT;-W!7P$(81<QZZB)@[I$P`"]A#S,3<
M,3&3T#),Y>%FH]E*Q$I'KD<LI*,D6Y';!^S<)"9)=J[:JD4(8HB`E,`Z`JC?
MW+.,Y<+IXP9D29KK0"UOWKC"3>)U,BUE&T@SNJ*:+!3:F>2:+N]@5W'!`X``
MTT!+7Z)F48G)'IT82CV3E!64Q@:YL97"V3$059R,!/OGC0JZ9AW`9W"RK9<H
MT`#%/]0Z`E@T`M`>#J%(`B80`"A4PB(%*`4\1,80*4!'I41`.N@/8C3KY>(C
MY`'ZP_5H"`SU99*?Y99_XN>F%CBX#P:V1Y@^:\[7"U:DE0M3'MEI.G5OED8D
M[ALWD04>-EWOR;@X)*J)-@,%#@.@"Y:<0^>K%HT8LO4_GV3-FW;LV;-KQ1PN
MBV:MVZ1$&S9!,KD02;H)D*4H`-`*%*Z`JT^I)@W,OI]<YK&S"\R8[RA>-WRT
M/R&@<GDLV,L0D]?%OW$*=XPZ]O6TJ>$C%U'#9OWBM]I54'VXY:F$=`7@\,Y5
MMO.&*,;Y>M!<CBW,EV5;UZ11TS@H"*$]&I/3LE#`/1RP<"H@J'Z*B1@\0T`Z
M?\']K0$)O-5)_"<C;B?G3%!&7A;4>LES")4UVY(A&+5$HAXBD[CSE$/K#ZM:
M(N_"TO='[@]0U.=/;@OX;+V'TI58[.)CO5SHYJIY<"5'2J6UO-IP6*JW/$Z7
M,G.BR.7ZE0Y_'%_L(7LOW9$W;E)4H1[!UN,T(L!R@#R422HJLDV/0Z2!1VJ&
M`-P4`=6KT;ZF6.V9VW>KN1^H6N+$7%$=P1R^*(B\%\47D5#<6BI=(]ENBMM.
M'IP=7]+CXA>VUEUVUA9B><2@NI^Y5R1S5PHJ/>1CF8]Z4>I%)1-!,RAB()@0
M"[*&I[NIN;9ZSS66@7NMWFH22ZMJ#$9$F=<K(U6M&-K1O!N*<D,17.V4?*R/
M(Y(HZTQQ7PJO'S.]F,Q-496(9O'/_9IBT8QI+$,8O935E&8E/)F)0`,=HHJ4
MYA&H["CK*-[UJFCU2ULG7J_Y?>Z(CIUKZUD<U,6OK5G%>!2[?;UPJRN7.KHG
M5;557GY^-**#3=V3BE8N+;G%SN21[A1%F^W_`##V&53$QCBW44W'<QRY0#>@
M81`2F`Y.H:B)O'JXV*QN=LZPY)]-17)!*YU96*O]I^+GHF"I5?$OC2=M72P,
MNHJ-55Q1$XKX@4W3/'DW:Y2J$6)N,8024$Q=@`(B8HB4-HE(%0*`!7SU`C=&
MKWEW=R1VCWO<N9K:XM>Y^#$1M>-:(9=T;3\ULL<M6S-8KJJN%&I5</@3I\<X
MIY"8-Q='/TC(/$[2CEED3>^D+WN/4RG#R-V7!1$/+7Z(NW72Y=#Z([9T>ZC=
M#<,T^BL=BJ9GR/Q_6J1$W3+%=[EO+MF+4<J?,E!PKXO>T,:VG.WW?UR1%GV?
M;,<YEYVXYY\A'QD7'LDS+N'"[EPHF01(FF.TA:G.;V2@)A`!S52F!;R+5*E=
MWTP<B6WSM]2+F!S0DY%NL7']O0F,L!VI(KI%EX2P)9Q(QZ5QMHPYA.C\U$0Z
M@K*$]DBTHH4P[@&H%DH0J'M#7J`B/AN$!`>M*!0P^(:`A[]<S"MO95X`9!N2
M27CF-P86EH/*%I/9%RBS,X68N4X29M]HY6,4>[/04HJ0B9:BJNFF&@(R?[?;
MF_95K0UX</LH7<PMMU(7(K?6%'EPR";*/F%YM)-*[[-CWSSM-TI`7S9)^U;B
M)>]W%RDWF+U`M=E]OJ2HE-02^R-!+M+4Q3^XHF81J`A].@*C/]R=>EJS60^,
M%GQ5PPLG<EL6WDN3N"&8OV[I["-)IY;;>*4EDFJZQV0OQC%A23.4JB@)B8``
MN@)I_1OO6U+L].WC7'6_<,/,2=HV=(6Q<\8S>MUI*!G6-RSBCN*EF2:QEV;I
M-!R0^PY`$2*%,`Z`$OUR_3\-R*Q&3DABN!!]FG"4(X4N&,8-]S[(&*6Q5G<M
M&T3**KR9L\#J/F0%J=1N*Z0")A3```Y]#/U.K;@+>:\.>05Z,H5A'G.;CU>U
MTR*+"--'.%CG<8MD95^JB@U%@X5[L(HL)$CHG4;;MQ$RZ`L#<TN*5B<W>.-X
M80NMPDU2N!JC-69>+4B+P]H7I$@JXMVYF(I*'%P+9<PI+D(8>ZU54(`C6H`5
M5N$&>\T>B[R>NG!_+BS)V#PIE)^B2X)>/;/)>`2D6*JK*`RYCQZU(HUN*+<M
M!!&4;)&^=*V,3<B59`"J`7*<>Y%L3+-I1%^8TNZW[YL^>:I/8FX;9DVTK&NV
MZI`,406;G.*2H#4#IJ`15,U2G*4P"&@.N<JD:H*N7"J35N@0RB[ER<J+=!(@
M"915950Q$TDR`'4QA``\^F@*X?J6^H;:F?;_`,9^G3Q6O$MT3F9\MV-8N:,E
M6>].>*A;=/=C#[WL&V9]B:DC*2*+10TFZ:'.@V:)&2!7N*&*4"?;)N2L;X"Q
MI.Y!R3<T59F/[%@CN9&7F'J#=%./C6I4D6C<72I#/I!V0A4D$B"9198Y2@`B
M.@(&_1CN&/Y8\F.<_/2Z9!!2_KQN^'QO8]K.UD59BQL7%:-IA@FBU6,HY9MW
M\<QCF@F+[`J,UPKXU`L7!T`/HVT]H`\*4'<'AU#QT!`Y_<)X9MZ]^%T5E1TO
M%Q]TX2R%!2<*=ZX0:NI:#O)RUM>Y8!AWA*HZ77%5F[*D6N[Y,>@>.@&!_M_>
M;]F/L0O^'61KNC8&^;%N*5F<0-KB?HLPNNQKC6-+25O0CEXJF@M*VK-G<J?*
M$,"QF;LITR&*0U`+-5/@^Z:E:TJ2M/IKNV4\_'PT`./(CCU`9UAT$UG'W/=D
M("Q[=N`B?=!OWTB"JPD4`H9U%N5$RB8H"!TS!O((#6L:.XWMPVUW!:$RTOU;
M#K]DBNMY4XYJ+1'JF*)CRKAR+LVGNZXV[?969EMUIF:G/S3S^)%U*<1.0EM2
M1T65II7`1%54B3RWI-BY:.$*T*L/SCEJ[;F.7WB*$W5\]:F-=[+^X#;]W+IM
MGI3;YON_O('J^L:5YJQO/+@2%LNI.TIZMN)7QPJROK:C?5AYKYGWF^#N2I0;
M%6QG/`FV3(@B0CV*`$D2UWE*4']/C"-3:]MMVY=S=FZ)L.@7SK>)*(B_#P*;
M)NK9SIED2ZARJI^^4PUR4?E0'_;6?,="/:L0*9>)`/@IF((U^\?`-W355U7H
M?W37;+=UMM^_2:&U;%5<."8TQ7`^(=R[+C6;-=P^OAC]9R<EQVY)2ROQL<S7
M=,1(%#JO(8@J"F0$BG$!DJ@.P@!]FK9U+M@[D-9U#/)MN^K*B->^3"-J>*<<
M<5KAX%8M]Z[*M(&O^]-7*E*)3BGRH/SA#@Q-DG8ZY<OG8-8]DN@^2LYB]%^Z
MD738_=3).OFW_1H1I5BE,+=$3F4`-IC4$=2;Z`]@6NVFNV^[.KDR,M[-_N16
MC'*]'/2BL62N5$RN1%I1Q8NZ>K,,MM)9:`KTE>U6YU1&T14HM,55:I\W'R)3
M$B=I,B9"E*0A2D(0*`4A2E`I2E`I=H%*```````!T#6V&"WABBC8C4;[<:,1
M$X(U$HB)\A@.9TLBHYJ^ISJO\_Q@4Y\]//BUR@O56^<ZV;=%^OU6<<Q"$=Y-
MR)'V8BE%I=MHLWLJ'N-C;J+PH&$3K@AW5#!N$?H[OAP/KX<!FB^C;Z>T:\3D
MK6PM,6++)HJ(IS=AY4RA:<P1)4**)IR45=B+K8?H(EW[-P`-*AH"2R&B&L#"
MP\"P%P+"$C(V'9"]=NG[L6,8U19("Z?O%5GKUT+=`-ZRISJJ'J8QA,(CH`%<
MQ^F1Q`Y!WM.7]F2R[QOB9N.40F)",DLLY+2M)N^;M$&9#QEHL;F:V]&)BD@%
M2(MREW5-XF&H#9NO1;]-5V@"(\;(UF<H@*;EC>V0F[E,Q1J11-<ETF,59,>I
M34J!@KTT`04+P1P!;V#[BX[Q*.36V,+FN!O<DBR-F?**]PH/6JC%1%K$7DM<
MY[IAH<3L2"=DW=$;&]H-E##4`?D/1?\`3?*LN\D>/2=PR#M0RCR1N/(.29B0
M=',-=[E\YNL5U3UZB(B(CXUKH#ZD%Z0/`NT9IM<=BXMNG'TRU>M'Y'=C9=RE
M;)E5V3I)T@+L(ZZTRO""=$`.14#E.2I#5*(AH"3"A#$%N<F\O:[(IG)O*LEV
M]IR[3E$JI>WT/4-HB--`1@//1E]-^5F)^=E^.$4_>W'*2<R^05O"^4HQ!]*N
ME'KO[KC6EP-6<:U^87,":*1`21)0"``:`)SCEPSP+Q05N(^$(.Z[=:7,RCF+
MZ$F<CWY>,`T0C%EUVI(:(NR>F64&8#N#`<[4J9E"`4IJ@4``!VLKX9Q9G*U7
M-DY=Q]9^1[6="<QX2\(5K,,D%3DV"Y8F71%U&NP#P6;*(JA3W@$=`1S1GHW<
M8K#F'L[@'(/)?C&]?N!<.6F#\X7'`09S&'?7[EETIMH82B(E*!]X$*/0=`?7
MG?2=Q;D!N+#-7)?FQFZ$.78O;5\<AYQI;SD@^\F]BK7CX%%XD<*@)3B-:Z`=
M_#7ID<%<`7%;5YXLXZ69!7M9[HC^V[Q?N9ZX+CB)%-)1`D@R?3<J^*V>%26.
M&\A2^\/TZ`6:?37XB<C,@2V2,W6%<N0IR7.R65C)G*&1R6BS68,$(QNI$6<P
MN5G;T.<&K<!,9N@03',8P]3#4!MX_P!'C@!;\F2:LS$=Q8_E4BI`$A8>7,KV
MH]5*@N1PFBX=15WI+KH=PG4AS&(("(;:".@)-DTRI))HDKL23(D3>(J&VID`
MA!.903F4-0H5$PB(CXZ`CLR;Z5/"O,MZ3]^94L&\;_F[AN&0N=TWN;+F37L"
MTDY)4RS@L+;O]3EA8)H0QQ[:35%,B91H%`T!QKST7/37=$3(CQR8QBK<Y5VK
MZ*OC(K%ZW<)FWI+(N$[K.HDLF8*@<H@(#X:`)7_PDP7_`./7_C1V\E?[6_U!
M_4/RW^\>3/ZK^<^]?O3Y;^O_`.H_ZQ^Y^][/R7S?RW9^%L[?30!;K#0XT`?`
M/Q>'^>N/<:WTO>UJ>',ZW(JKZ<'&G;0/K'J(B(B;[3".N'2896YW-\46GTB)
M):_S*HL7*OC_`%5,4_#\#:Z\SO"3];\AW4M?X9D`$/,/M#_Y:[*.\)/UOR"E
MK_<,"01'=4H#3Q[91'_$:CYZY;1ZJQ5D1U.&;\AUN^[(N#<WPX&"EH8/$>GB
M)AI^+:(B`?9370C5CF1GMHB*B^K-5?FHGUA)$<M$B5N'$V:]!]'+WO-FMJSK
MHN$C]G&'A(*2E"R$@W.Z9-3,FRBX*.6R;AJ=9*I*"4#E$:Z`:+C-/Y#O3&R=
M^9%DP>2%Y2;F5A6",<C&,8>W4Z-(Y%FV(!EP(^%$ZXF6.<X[PH--`$,`#6@!
M4?(!':`C3I4?(OT^=/#0#98S4RPHUN/_`'8;6LU>%N)V2V2VN=8Z9[<`H?*J
M2/=,<`>&-]`@-*U`-`.:`"/@`C3Z`$=`8T!RZ=ZVJI=ZM@$G&A[R0APN!>WT
MP5.]1ACK`BF^7$J0H(I*'.4"5/N,/EH#J-`"?<U[9#D>4%IXIMZXV3>SVD`G
M?%X-V$05.5:LFX+IMHB0EU5W`JH2KH4C`5-),=J@!7I70!8B`@/4*#]%*:`Q
MH#-!`*T&@^`TZ#H!4$:B`#0/'ZOQZ`0@(>("'XPIH!4$0K0:!XC3H&@%0>G0
M>OAT'K^+Z=`(0$.@@(#]`]-`8T!F@@%:#0?`:=!T!C0&[^#^UH#RK_S#?9_P
MAH#7H!:`6@%H!:`6@`NYC7#,2</9F$[515?W)EB?10=1S9;M+GMJ+52<R'=6
M`HBU9.E@`BJI@H5$AA\M`?+CX:^K9Y"X@M..R!,S:2%G2\G?EILQ2:61;5K1
MS`D7;R$7%-D2@W2=OAVHJ.#J.'!DA.-`Z:`<SE->=Q638#E>$F5HAS,')`Q2
M$,ILNJ<N>6/\O#1T,H9%PFP9$W'7>+`45A32`B>T3";0#C62C)8SP]%&R!./
MIJ3M6U#R-T3;U8RKA55JV5D'R'S"M%%00IV2"83";:'4:Z`$23NV]KIP5D#D
M9=-T3]K&59.W6(K6@Y->+C(!HA($:03]^U:G2"X)68>E$Q_F#*)"C[()]=`&
MC:,],3&,;<N>6,WC9N2LR-FI%9ZF?[O:/58E-VX<+MTS)*?+%.0RNT!*-!I7
M0$=EN0DG>>.\^\FYZ\;EB+E=J3"%F35MOUK<*>&LXY6S$5F2"JB3F.>/B(D*
MBH<Y?8&@U$=`'IA.XIVY,,V%=5[+'+,O[2:R4N[53!'O`5)4P2*A.@)'=,2D
M6,'AU$=`"'@R*NS,-Z9JRH27D;/M6Z[B/#I7+%"5&XI&WK<!9%G`6\]<(+DB
M8Y-,I%';PH&4$P@DD)?;'0#S\.9>\9W&$R_NJ8E[A;)W[=#"UY:96%U(N[?8
M.BMDE%7)O;52^93/M$?KT!T\IDLUTC>$G#SA[2Q;C\[QG=.0$2I'D9Z7C0-]
MXQ-H'<%<-&[..4HBL]%)511P/:1)4!-H#G>*3.Z9NU[ARG>$[<,NID675>VR
MUFWJRWW59L<=5I"*)-2"FS;OGJ-5%3IIIBH!2"(5T`TF3[HRP]Y,6!8=EW:^
M&7;)R$]+P4<X.A9T%;RY!2B5;A9=D5I9PBR.+AV957:L95))(I!]K0!4XTQI
M.V$_NIU-9+NS(2-Q.6+IJVNA1`Q(4R"2HO@8$0`$DR.US;]A0*0I``H`.@!2
MG[DRW=?**+L^T;R>)!9L9)/[X!LY.2PK7:2":H1S5PP[0#,R;&-4(90[LQ@5
MD#AM`B28U`XRQ[YO!X]S]>Q,EWR3!5O$48DNN7E_FKAE9.&`Z)F=E+':*-(M
M[<#]3VU$6P]ANJD0A04H(`%UQ@87NQPY;CG($Q+3$W/*.[@:A-N%'LG&0DJH
M"\-&.WJ]'#I8&@@<3*4-52E"TH`'B5R.>ZC7@\AYTMIXMQ^I(M[LR"@#=23F
MYB-2K*PEI*N4%VK)I%J[4G#X4U%#N1!)`H&J?0'*<4FUV3MN7+E*[;@N66'(
M4VY5M1E<3X7)HVRHM59I`J_)I$1:)/GQ-PK'*F03D('3K40"Q`*``?0`!XB/
M0`IXCU'0&_\`@_M:`\J_\PWV?\(:`UZ`6@%H!:`6@%H`8;MQ1DE;.K7+UF2E
MFKI!98V:1E>*4N<]N&[IU7$G%I18`5^HN)_:3%1$#;A`34T`[=AX[8V2:;E%
MGKJ>O"Z7)'MT7;(%(5_*KID$K9JV1*3M1<-&E-M:M4Q,5,O4PB:HB`U.4\/7
MKD/+./;M9W+#1=G6/'O#IL7+)=]+MKC=JF`9V-;&`8Q9\U:@F#95<QB-U2[M
M@F``T`\MUV4PN6P9S'BSQZ#";MMY;QWR[@SZ0[;IH+8KU99<>XZ=)F,4Y]X@
M)NM-`#^WP#<]RP..;!R%)P+?'.-4(D30%LJOW*]_24*BDC'NIU9\W;(Q<4F=
M+NF:)%6.)S#\6F@/O\J[P6M##LC#0H`G<%^.X_'ELM6U"*=^X%$V3DR"8&`0
M3;1@'#V0]D3%T!SL5@6Z9#'EDX8NQ_;D=C:UDHT9YK;IY!::OHL<X^>1CI`'
M+9NUA8UR_'N.P(9PHL)0H8H:`?W(-LS,_CBYK.LQ]'VW)2EO+6_$O7**YF$2
MW<H`P,<J+7XO_3L#&*F4OG30#1,,49&MR*MO&MFW+:D)BEG8R=KSARQ3TU[D
MF%*EF9B$>5*Q*I)E74VF5`>P*HGH82@&@'D1M)C`V&K8ME@2`;,+8>04&JD4
M3)1RIHY1HU=J"F7O.%R+B"IS]3G.(CU$=`!4_P"+67)7!L/BB3OZUP4@Y-NK
M'Q<:VF&4*\9#(+R$D\N&13WR<M+.A<F!(H)I(EW&$=QZ'``TK#ME:T;?0B74
MDI).BIM05!-$6D6S0;-F[%".@HJJAHN&9H(`FBF8QU3B`G4,8QA'0#=8RQ$_
MM*_,F9)NB58S-VW_`"X$9K-6ZQ$(2SF1C?=<"B#H!/WQ*D4ZM!VCL``Z!H!\
MG@.19N@9&0*]^76^2.Z`XMB.P3,+<[@J?MG1(K03`7J(!H`5(#`%X6IB"_+8
MA;NB`RQDN1?R%X9`<,WJJ"RDR[.#I-D0H"\VM(U0Z;<@@5,AE#"/E0#3?_'&
M4E;`Q+BRP9&WXJSK+G(V6N=E-MWBR5RGC.VY2<KHLMIGYEY,RJRR*JB8G$Y?
M:]D*`$<C;3QI:4A;S2;D'DJZC99`)Q\HF=8DG*(.B_."1&B31FU75+V4$2@1
M!(I2E#IH`(W?%K+TM@AAB.3R!:X&B91'Y"-CV<JSAGD>:46D)%U<LB4#2<_*
MJF<?"*4A$"B`[MZFTY0#3L&U'-GV\VBGDH,FZ`C4J@()`SAXU-HR;L6L3`QI
M1,$?%,6[<I2%,8RR@U.J8QQ$=`=KH#=_!_:T!E3M[QW;Z]*TVT\`^GKH#Q\+
M^9^[H!?"_F?NZ`7POYG[N@%\+^9^[H!?"_F?NZ`7POYG[N@,?`_U^/\`H\:A
M^6M-`>A[?GW?/QV_;H#S\#;^GMZ_J;:5Z_5[WC]>@%\#VO?I4-WN>/3;N^OZ
M-`9'LT&O=I0WAXTI[6W9[=?Q=:Z`!W.!;8'+N-_ZR6SB66&YB_[7A#-<:'L<
ML[5'>#8TL[(H9UMV[A?@"M/#KH`WD*=A'N_,BIVD^Z*P(`J*O;#N]X&XBW!;
M=7?VQ$FZNWI30&P>S3KW*5#QVTK7I]M=`9'M^?=^W;X=*_EIH#`=KR[GCY;?
M'\^@,?`_U^)?U/']'[:>&@/7PZ?Q:?LT\?SZ`Q\'S[E:_P"GWJ#^6F@$/9\^
MY]NW\/#0"#M4Z=RE!\-M*>?U4T`O@_S/>#]7WNE/VO"F@%\*O\2M?]-:U_SK
MH!?"K_$W=*^[7Q&GU^.@%\'R[GB/ZOCY_;H!?"_F?NZ`V^QVOT]N[ZMU?\M`
#?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
